This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Grifols Buys Novartis' Transfusion Diagnostics Business

Stocks in this article: GRFS NVS

NEW YORK ( The Deal) -- Barcelona drugmaker Grifols (GRFS) on Monday, Nov. 11, went shopping in California for a second time this year, picking up the Emeryville-based blood transfusion diagnostics business of Swiss drug company Novartis (NVS).

Grifols would pay $1.68 billion for the unit, which makes equipment and chemicals for screening donated blood for infectious diseases. The division had sales last year of $565 million.

"The sale of the Novartis blood transfusion diagnostics unit enables us to focus more sharply on our strategic businesses while providing Grifols with a platform for global expansion," said Novartis CEO Joseph Jimenez in a statement.

Grifols earlier this year bought 35% of Hayward, Calif.-based Aradigm for $45.4 million as part of a drug development deal. The duo are developing treatments for lung diseases, and Grifols will commit as much as $90 million to the cooperation.

The buyer is also the world's third-largest provider of plasma-based therapies, making a reliable blood supply essential for the Spanish pharmaceuticals company.

Novartis has made few major deals in recent months. Analysts said the sale would allow the company to focus on more pressing matters.

"The deal's positive since the unit is lacking the necessary size to compete and is less profitable then others in the group," wrote Independent Research GmbH analyst Christoph Schondube in a note. He has a hold rating on Novartis shares.

Novartis acquired the blood transfusion diagnostics division in 2006 when it spent $5.4 billion to buy the outstanding 56% of Emeryville vaccine maker Chiron.

Novartis shares gained 1.1%, or 0.75 Swiss francs, to 71.70 Swiss francs ($77.94) in afternoon Zurich trading, while Grifols rose 5.2%, or euro 1.61 euros, to 32.56 euros ($43.64) in Madrid.

-- Written by Andrew Bulkeley

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs